Immunology
FDA committee gives nod to Janssen COVID-19 vaccine
A single-shot COVID-19 vaccine from Johnson & Johnson's Janssen Biotech subsidiary received a positive recommendation today from a U.S. Food and Drug Administration (FDA) advisory committee. Should the FDA grant the product emergency use authorization, the vaccine candidate will become the third to be made available in the U.S. Read More
New open-access toolkit helps research labs study SARS-CoV-2
One of the most important factors in fighting the COVID-19 pandemic is large-scale scientific collaborations and knowledge sharing. One international group of researchers has made its simple, robust toolkit available to laboratories around the globe that are unaccustomed to working with coronaviruses. The details can be found in a PLOS Biology paper published on February 25. Read More
Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy. Read More
Proteomics helps researchers pick the best anti-SARS-CoV-2 nanobodies
A new high-throughput proteomics-based strategy to identify tiny antibody fragments -- called nanobodies -- may provide an efficient and effective method for developing therapeutics against the deadly SARS-CoV-2 virus -- including variants. The findings were published in Cell Systems on February 15. Read More
Scientists identify missing molecular links to SARS-CoV-2, host interactions
Researchers have identified interactions between short viral proteins and receptors that facilitate the entry of the SARS-CoV-2 virus into a host. This evidence of molecular links, published in Science Signaling on February 12, may help scientists identify drugs that are highly effective at blocking the virus. Read More
NIH adds long-acting antibody COVID-19 therapy to ACTIV-3 master protocol
The National Institutes of Health (NIH) has begun a new arm of its master protocol, the Accelerating COVID-19 Therapeutic Interventions and Vaccines 3 (ACTIV-3) study, which evaluates the safety and efficacy of an investigational long-acting antibody combination for the treatment of patients hospitalized with COVID-19. Read More
Deep-learning approach points the way to faster COVID-19 vaccines
A novel deep neural network can target the most promising multiepitope COVID-19 vaccine candidates in a matter of seconds. The new artificial intelligence framework, which was described in Scientific Reports on February 5, may give scientists an edge in the race against SARS-CoV-2 and its variants by reducing the time from vaccine design to clinical trials. Read More
New COVID-19 vaccine platforms emerge, are effective in preclinical models
Additional vaccine approaches are necessary to fight COVID-19. Two new vaccine candidates have demonstrated their effectiveness in animal models, and their potential clinical applications are described in two new research studies. Read More
Recurrent deletions help SARS-CoV-2 mutate to escape antibodies
Researchers have identified a pattern of deletions in the spike glycoprotein of the SARS-CoV-2 virus that can prevent antibody binding, which is part of the body's immune response to a foreign virus. These deletions occur as a recurring pattern of evolution, according to a study published in Science on February 3. Read More
Researchers innovate drug discovery screening techniques
Researchers from around the globe gathered to discuss innovations in laboratory techniques such as phenotypic profiling and flow cytometry for drug discovery applications at the Society for Laboratory Automation and Screening 2021 virtual meeting. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter